The future is just around the corner

Five years from now, EXINI will be listed as a NASDAQ OMX Small Cap company. Our principal product, EXINI boneBSI with its BSI module, has become standard procedure in clinical bone examinations related to both prostate and breast cancer. Product development provides a variety of application areas as to imaging diagnostics.

Our markets are mainly Northern Europe and the USA, as well as Japan, via FUJIFILM RI Pharma. In recent years, sales in China have increased. EXINI has distinguished itself as a company with innovative imaging biomarkers, thus having contracted several clinical trial companies as partners.

EXINI’s business model has been reformed to accommodate new ways of distributing and offering our products. Cloud services are up and running, enabling EXINI to manage large increase in volumes efficiently regarding support and service functions.